Found: 94
Select item for more details and to access through your institution.
Ensitrelvir Fumaric Acid: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 6, p. 721, doi. 10.1007/s40265-024-02039-y
- By:
- Publication type:
- Article
Iptacopan: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 5, p. 599, doi. 10.1007/s40265-024-02009-4
- By:
- Publication type:
- Article
Dimdazenil: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 5, p. 607, doi. 10.1007/s40265-024-02020-9
- By:
- Publication type:
- Article
Adis summary of research: A 10-year observational study of the use, acceptability and effectiveness of long-acting paliperidone palmitate: implications for clinical decision making.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 5, p. 192, doi. 10.1007/s40267-024-01073-w
- By:
- Publication type:
- Article
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease.
- Published in:
- Drugs, 2024, v. 84, n. 4, p. 441, doi. 10.1007/s40265-024-02016-5
- By:
- Publication type:
- Article
Adis Summary of Research: Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 4, p. 139, doi. 10.1007/s40267-024-01067-8
- By:
- Publication type:
- Article
Tirzepatide: A Review in Type 2 Diabetes.
- Published in:
- Drugs, 2024, v. 84, n. 2, p. 227, doi. 10.1007/s40265-023-01992-4
- By:
- Publication type:
- Article
Correction to: Nedosiran: First Approval.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 2, p. 53, doi. 10.1007/s40267-024-01050-3
- By:
- Publication type:
- Article
Correction to: Tezepelumab in severe asthma: a profile of its use.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Nedosiran: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1729, doi. 10.1007/s40265-023-01976-4
- By:
- Publication type:
- Article
Tezepelumab in severe asthma: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 393, doi. 10.1007/s40267-023-01033-w
- By:
- Publication type:
- Article
Lotilaner Ophthalmic Solution 0.25%: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 16, p. 1537, doi. 10.1007/s40265-023-01947-9
- By:
- Publication type:
- Article
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants.
- Published in:
- Pediatric Drugs, 2023, v. 25, n. 6, p. 729, doi. 10.1007/s40272-023-00598-3
- By:
- Publication type:
- Article
Durvalumab: A Review in Advanced Biliary Tract Cancer.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 6, p. 965, doi. 10.1007/s11523-023-01007-y
- By:
- Publication type:
- Article
Correction to: Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Desidustat in anaemia in patients with chronic kidney disease: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 8, p. 279, doi. 10.1007/s40267-023-01012-1
- By:
- Publication type:
- Article
Correction to: Sparsentan: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Mavacamten in obstructive hypertrophic cardiomyopathy: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 7, p. 223, doi. 10.1007/s40267-023-01003-2
- By:
- Publication type:
- Article
Rezafungin: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 9, p. 833, doi. 10.1007/s40265-023-01891-8
- By:
- Publication type:
- Article
Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 5, p. 369, doi. 10.1007/s40261-023-01270-x
- By:
- Publication type:
- Article
Sparsentan: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 6, p. 563, doi. 10.1007/s40265-023-01864-x
- By:
- Publication type:
- Article
Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 2, p. 303, doi. 10.1007/s11523-022-00945-3
- By:
- Publication type:
- Article
Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 1, p. 169, doi. 10.1007/s11523-022-00935-5
- By:
- Publication type:
- Article
Futibatinib: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 18, p. 1737, doi. 10.1007/s40265-022-01806-z
- By:
- Publication type:
- Article
Dorzagliatin: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 18, p. 1745, doi. 10.1007/s40265-022-01813-0
- By:
- Publication type:
- Article
Correction: Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
- Published in:
- Drugs, 2022, v. 82, n. 15, p. 1549, doi. 10.1007/s40265-022-01790-4
- By:
- Publication type:
- Article
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema.
- Published in:
- Drugs, 2022, v. 82, n. 13, p. 1403, doi. 10.1007/s40265-022-01763-7
- By:
- Publication type:
- Article
Correction to: Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
RTS,S/AS01 malaria vaccine (Mosquirix<sup>®</sup>): a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 9, p. 373, doi. 10.1007/s40267-022-00937-3
- By:
- Publication type:
- Article
Correction: Estetrol/Drospirenone: A Review in Oral Contraception.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Tirzepatide: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1213, doi. 10.1007/s40265-022-01746-8
- By:
- Publication type:
- Article
Estetrol/Drospirenone: A Review in Oral Contraception.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1117, doi. 10.1007/s40265-022-01738-8
- By:
- Publication type:
- Article
Correction to: Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
- Published in:
- Drugs, 2022, v. 82, n. 7, p. 811, doi. 10.1007/s40265-022-01720-4
- By:
- Publication type:
- Article
Correction to: Dasiglucagon in severe hypoglycemia: a profile of its use.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Molnupiravir: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 4, p. 455, doi. 10.1007/s40265-022-01684-5
- By:
- Publication type:
- Article
Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 2, p. 219, doi. 10.1007/s40256-022-00521-0
- By:
- Publication type:
- Article
Dasiglucagon in severe hypoglycemia: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 3, p. 105, doi. 10.1007/s40267-022-00894-x
- By:
- Publication type:
- Article
Regdanvimab: First Approval.
- Published in:
- Drugs, 2021, v. 81, n. 18, p. 2133, doi. 10.1007/s40265-021-01626-7
- By:
- Publication type:
- Article
Correction to: Regdanvimab: First Approval.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
FKB238: A Bevacizumab Biosimilar.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 9, p. 825, doi. 10.1007/s40261-021-01065-y
- By:
- Publication type:
- Article
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
- Published in:
- Drugs, 2021, v. 81, n. 13, p. 1559, doi. 10.1007/s40265-021-01580-4
- By:
- Publication type:
- Article
Hetrombopag: First Approval.
- Published in:
- Drugs, 2021, v. 81, n. 13, p. 1581, doi. 10.1007/s40265-021-01575-1
- By:
- Publication type:
- Article
Amivantamab: First Approval.
- Published in:
- Drugs, 2021, v. 81, n. 11, p. 1349, doi. 10.1007/s40265-021-01561-7
- By:
- Publication type:
- Article
Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice